Hematologic Oncology | Specialty

Dr. McCloskey on the Results of the ASCERTAIN Trial in MDS

January 8th 2020

James K. McCloskey II, MD, discusses the results of the phase III ASCERTAIN trial in myelodysplastic syndrome.

Dr. Goy on the Results of the FLYER Trial in DLBCL

January 8th 2020

Andre Goy, MD, MS, chief, discusses the results of the multicenter FLYER trial in patients with diffuse large B-cell lymphoma.

Itacitinib Misses Primary Endpoint in Frontline Acute GVHD

January 7th 2020

The combination of itacitinib and corticosteroids did not induce a statistically significant improvement in overall response rate at day 28 compared with placebo plus corticosteroids in patients with treatment-naïve acute graft-versus-host disease, missing the primary endpoint of the phase III GRAVITAS-301 trial.

Brentuximab Vedotin Solidified in Hodgkin Lymphoma, But Toxicity Concerns Remain

January 6th 2020

Seo-Hyun Kim, MD, discusses frontline treatment considerations in stage III and IV classical Hodgkin lymphoma and exciting combinations on the horizon.

Dr. Damon on Optimal Treatment Regimens in AYA ALL

January 6th 2020

Lloyd Damon, MD, discusses optimal treatment regimens in adolescent/young adult acute lymphoblastic leukemia.

Ongoing Research Poised to Add Options for Myelofibrosis Treatment

January 3rd 2020

Jamile M. Shammo, MD, FASCP, FACP, discusses the current treatment paradigm of myelofibrosis, criteria for ruxolitinib resistance and intolerance, and promising agents on the horizon.

Experts Provide Insight on the Biggest Advances in Oncology in 2019

January 1st 2020

OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.

Pazdur Followed the Pathway of Greatest Resistance to the FDA

December 30th 2019

Richard Pazdur, MD, set out to be a leader in medicine and a teacher of doctors. He achieved that and more, turning the oncology drugs section of the FDA from a poorly understood and lead-footed division into a fast-moving and patient-responsive entity.

AML Research Efforts in Full Swing After Decades of Stagnation

December 28th 2019

Melissa L. Larson, MD, discusses available treatments for patients with acute myeloid leukemia, as well as others that are in the pipeline.

Novel Approaches Across Non-Hodgkin Lymphoma Subtypes Demonstrate Continued Benefit

December 27th 2019

Jean L. Koff, MD, MS, highlights exciting advances made in follicular lymphoma and the promise of CAR T-cell therapies in other lymphoma subtypes.

Influx of Novel Agents in AML Leads to Role for Up-front Molecular Testing

December 24th 2019

William G. Blum, MD, discusses the introduction of novel agents into acute myeloid leukemia treatment and how this is impacting the role of molecular testing for patients.

FDA Approval Sought for Selinexor in DLBCL

December 24th 2019

An application has been submitted to the FDA for selinexor for the treatment of patients with relapsed/refractory diffuse large B-Cell lymphoma who have received at least 2 prior multiagent therapies and who are ineligible for stem cell transplantation, including CAR T-cell therapy.

Final Thoughts From ASH 2019 in CLL

December 24th 2019

Novel Combinations in Development for CLL

December 24th 2019

PI3K Inhibitors in R/R CLL

December 24th 2019

BTK Inhibitors in R/R CLL

December 24th 2019

Venetoclax in R/R CLL

December 24th 2019

Progression on Frontline Ibrutinib in CLL

December 24th 2019

Resistance Mechanisms Associated With BTK Inhibitors

December 24th 2019

Ibrutinib + Venetoclax for Frontline CLL

December 24th 2019